Entero Healthcare Solutions Limited — Investor Meet, 02-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Entero Healthcare reported robust Q4 FY26, with revenue up 42.6% (17.1% organic) and EBITDA margin at 4.5%. For FY26, revenue grew 31.5% to INR6,591 Cr, EBITDA reached 4%, and PAT climbed 36%. Management projects 23% consolidated revenue growth and 5% EBITDA margins for FY27, aiming for 50% operating cash flow conversion. The focus is on organic growth and integrating MedTech acquisitions, which now contribute over INR1,000 Cr annualized revenue. Management acknowledged Q4 minority interest normalization, asserting their wide distribution network is a significant competitive moat. The outlook conveys confidence in driving profitable growth and improving return on capital employed beyond 20%.